Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Recurrent fixed drug eruption caused by citiolone

Simple item page
dc.contributor.authorBarrio, Manuel de
dc.contributor.authorTornero Molina, Pilar
dc.contributor.authorPrieto, A.
dc.contributor.authorSainza, T.
dc.contributor.authorZubeldia Ortuño, José Manuel
dc.contributor.authorHerrero, T.
dc.date.accessioned2024-01-29T09:21:23Z
dc.date.available2024-01-29T09:21:23Z
dc.date.issued1997-05-01
dc.description.abstractCitiolone (N-acetylhomocysteinethiolactone) is a thiolic­derived medication frequently used in Spain and in other countries as a mucolytic agent for the treatment of certain hepatic disorders. Mucolytic drugs have rarely been implicated in the fixed drug eruption etiology. We report on a patient who presented several episodes of fixed exanthema related to citiolone intake. The patch test with citiolone (10% in dimethyl sulfoxide) was negative. The diagnosis was confirmed by a positive controlled oral challenge test. Other mucolytic thiolic­derivatives (N-acetylcysteine) were tolerated by the patient, thus crossreactivity between these drugs seems to be unlikely.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationde Barrio M, Tornero P, Prieto A, Sainza T, Zubeldia JM, Herrero T. Recurrent fixed drug eruption caused by citiolone. J Investig Allergol Clin Immunol. 1997 May-Jun;7(3):193-4. PMID: 9252880.
dc.identifier.essn1698-0808
dc.identifier.issn1018-9068
dc.identifier.pmid9252880
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/9252880/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/95775
dc.issue.number3
dc.journal.titleJournal of Investigational Allergology & Clinical Immunology
dc.language.isoeng
dc.page.final194
dc.page.initial193
dc.publisherESMON
dc.rights.accessRightsrestricted access
dc.subject.cdu616-056.3
dc.subject.keywordFixed drug eruption
dc.subject.keywordCitiolone
dc.subject.keywordCrossreactivity
dc.subject.keywordMucolytic thiolic-derivatives
dc.subject.keywordN-acetylcysteine
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco32 Ciencias Médicas
dc.titleRecurrent fixed drug eruption caused by citiolone
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number7
dspace.entity.typePublication
relation.isAuthorOfPublication31d939f5-0cc2-4cea-8f6b-aad05509bbbf
relation.isAuthorOfPublication.latestForDiscovery31d939f5-0cc2-4cea-8f6b-aad05509bbbf

Download

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Recurrent fixed drug eruption caused by citiolone.pdf
Size:
235.56 KB
Format:
Adobe Portable Document Format
Description:
Citiolone (N-acetylhomocysteinethiolactone) is a thiolic­derived medication frequently used in Spain and in other countries as a mucolytic agent for the treatment of certain hepatic disorders. Mucolytic drugs have rarely been implicated in the fixed drug eruption etiology. We report on a patient who presented several episodes of fixed exanthema related to citiolone intake. The patch test with citiolone (10% in dimethyl sulfoxide) was negative. The diagnosis was confirmed by a positive controlled oral challenge test. Other mucolytic thiolic­derivatives (N-acetylcysteine) were tolerated by the patient, thus crossreactivity between these drugs seems to be unlikely.
Download

Collections

Artículos